tirzepatide-for-treating-type-2-diabetes-guidance-ta924 2023-10-30T09:57:35.148Z 0a7bdd5b-d027-48a9-813f-707b8f7e2d8f mas_evidence_types:Drug%20best%20practice%20guidance Guidance and advice NICE recommends tirzepatide for type 2 diabetes in adults, only if triple therapy with metformin and 2 other oral antidiabetic agents is ineffective, not tolerated or contraindicated, and other specific weight related risk factors and patient parameters apply. <p>NICE restrict use to patients:</p> <ul> <li>With a BMI of 35 kg/m² or more, with specific psychological or other medical problems associated with obesity, or</li> <li>With a BMI of less than 35 kg/m², and insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related complications.</li> </ul> <p>Lower BMI thresholds (usually reduced by 2.5 kg/m²) should be used for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.</p> https://www.medicinesresources.nhs.uk/tirzepatide-for-treating-type-2-diabetes-guidance-ta924.html https://www.nice.org.uk/guidance/ta924 2023-10-25T00:00:00Z 2023-10-25T15:25:30.815Z